Monday, January 20, 2014
Inc.'s Male Fertility Panel of genomic DNA methylation markers is being
developed to detect epigenetic abnormalities in sperm that can indicate severely
reduced fertility. The company expects the panel will help urologists steer
some patients away from in vitro fertilization and toward other options
such as a sperm donor or adoption.
According to co-founder,
President and CEO Alan Horsager, the molecular causes of male infertility are
poorly understood and current methods to diagnose suspected cases of
infertility rely on crude measurements such as sperm count and motility.